PMID- 21517254
OWN - NLM
STAT- MEDLINE
DCOM- 20120530
LR  - 20170308
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 12
IP  - 1
DP  - 2011
TI  - Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) 
      gene amplification of breast cancer in Indian women.
PG  - 179-83
AB  - BACKGROUND: The concordance rate between immunohistochemical (IHC) and 
      fluorescence in situ hybridization (FISH) results for HER2/neu according to 
      clinical performance is controversial. The present prospective study was 
      theerefore conducted in Indian breast cancer patients. METHODS: Fifty cases 
      (n=50) of invasive duct cancer of breast tested for HER-2/neu by IHC and scored 
      as 0, 1+, 2+ and 3+ by pathologists were further analyzed by FISH using a 
      commercially available double-color probe, and the findings compared. RESULTS: A 
      total concordance of 82.0% was observed with a Kappa coefficient of 0.640 (P 
      <0.001). A high discordance was observed in 30.0% of the patients with IHC 2+, 
      7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+. CONCLUSION: IHC can be used 
      firstly to screen the HER-2/neu status, and FISH can be used as a supplementary 
      role to IHC and 2+ and some negative cases. And only those cases with HER-2/neu 
      status of IHC 3+ or FISH positive should be treated with Herceptin (Trastuzumab).
FAU - Singhai, Rajeev
AU  - Singhai R
AD  - Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, 
      Mumbai, India. dr.rajeevj@gmail.com
FAU - Patil, Vw
AU  - Patil V
FAU - Patil, Av
AU  - Patil A
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Breast Neoplasms/drug therapy/*enzymology/*genetics
MH  - Carcinoma, Ductal, Breast/drug therapy/enzymology/genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - India
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*genetics
MH  - Trastuzumab
EDAT- 2011/04/27 06:00
MHDA- 2012/05/31 06:00
CRDT- 2011/04/27 06:00
PHST- 2011/04/27 06:00 [entrez]
PHST- 2011/04/27 06:00 [pubmed]
PHST- 2012/05/31 06:00 [medline]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2011;12(1):179-83.